MUMC+

Running trials

• Recruiting

  Assessing the Efficacy of a Single Measurement and Adjustment Strategy for DOACs in Frail Older Patients.

  2025-521362-10-00· Phase 4· Source

• Recruiting

  Prospective Data Collection Initiative on Thoracic Malignancies

  NCT06996249· Source

• Recruiting

  OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes

  NCT06476119· Source

• Recruiting

  Dutch Registry of Pediatric Cardiac Arrest

  NCT06938009· Source

• Active, not recruiting

  Lung Cancer Organoids and Patient Derived Tumor Xenografts

  NCT05092009· Source

• Recruiting

  DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.

  NCT07717437· Source

• Active, not recruiting

  Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia

  NCT04579367· Source

• Recruiting

  Distress In CErvical Cancer Patients and Partners

  NCT04475354· Source

• Active, not recruiting

  Elderly With Locally Advanced Lung Cancer: Deciding Through Geriatric Assessment on the Optimal Treatment Strategy

  NCT02284308· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute lymphoblastic leukaemia1 recruiting
• Atrial fibrillation1 recruiting
• Cervical cancer1 recruiting
• Childhood cancers1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lung cancer1 recruiting
• Mesothelioma1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide

  NCT03184194· Phase 2· Source